Nasdaq:VIVS
VivoSim Labs, INC.
A clinical-stage oncology biotechnology company advancing proprietary therapeutic candidates via a platform-driven approach.
Key Metrics
Investment Thesis
Bull Case
The narrowing net loss trajectory signals improving operational efficiency before commercialization milestones are reached. Investors may view the company as an early-stage opportunity with high upside potential if a key clinical candidate receives FDA approval. The current cash position of $11.5M provides a runway to execute on strategic partnerships or bridge to later-stage financing.
Bear Case
Persistent negative operating cash flow and deepening retained earnings deficit of -$342.2M indicate severe financial distress and an inability to self-fund growth. The sharp decline in revenue over the last three years raises concerns about product viability or market acceptance issues. Without immediate external capital infusion or successful licensing deals, the company faces an existential liquidity threat.
About VivoSim Labs, INC.
VivoSim Labs, INC. (NASDAQ: VIVS) is a clinical-stage biotechnology company focused on developing innovative therapeutics for oncology, with operations centered in the United States. The company leverages proprietary technology platforms to advance multiple programs through preclinical and early clinical stages. Key products are currently under development, reflecting the nature of its biotech business model.
Analysis
Management Discussion
VivoSim Labs reported a net loss of $2.5M for 2025, a significant improvement from losses exceeding $17M in 2023 and $14.7M in 2024, indicating potential stabilization or efficiency gains. Despite this, the company continues to operate with substantial negative operating cash flow (-$9.5M) and relies heavily on common share issuances ($8.8M) to fund operations. The drastic reduction in revenue from $0.4M in 2023 to $0.1M in subsequent years suggests a transition phase or specific project completion affecting recorded sales.
Industry Overview
The biotechnology sector is characterized by high failure rates and significant capital requirements, particularly for oncology-focused firms developing novel mechanisms of action. Market success depends on navigating complex regulatory pathways while demonstrating clinical efficacy in competitive therapeutic areas. Current market dynamics favor companies with clear paths to commercialization or strong partnership potential.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $370.0K | $109.0K | $144.0K |
| Cost of Revenue | $0 | $0 | $5.0K |
| Gross Profit | $370.0K | $109.0K | $139.0K |
| Operating Expenses | $18.1M | $15.2M | $12.8M |
| Operating Income | $-17.7M | $-15.1M | $-12.6M |
| R&D | $8.9M | $5.5M | $5.0M |
| G&A | $9.2M | $9.7M | $7.7M |
| Stock-Based Comp | $2.4M | $1.5M | $532.0K |
| D&A | $293.0K | $280.0K | $266.0K |
| Depreciation | $211.0K | $0.30 | $300.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $454.0K | $405.0K | $140.0K |
| Pre-Tax Income | $-17.7M | $-15.1M | $-12.6M |
| Income Tax | $2.0K | $2.0K | $2.0K |
| Continuing Ops | $-17.7M | $-15.1M | $-12.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-17.3M | $-14.7M | $-2.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-17.3M | $-14.7M | $-2.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $17.0M | $3.9M | $12.1M |
| Cash & Equivalents | $15.3M | $2.9M | $11.3M |
| Accounts Receivable | $152.0K | $33.0K | $30.0K |
| Inventory | — | $297.0K | $0 |
| Prepaid Expenses | $889.0K | $705.0K | $789.0K |
| Other Current Assets | $706.0K | $0 | $0 |
| Long-Term Assets | $3.3M | $2.4M | $2.5M |
| PP&E (Net) | $902.0K | $669.0K | $419.0K |
| Operating Leases | $1.7M | $1.3M | $867.0K |
| Other LT Assets | $658.0K | $445.0K | $1.2M |
| Total Assets | $20.3M | $6.3M | $14.7M |
| Current Liabilities | $3.7M | $1.9M | $3.7M |
| Accounts Payable | $331.0K | $627.0K | $1.6M |
| Current Leases | $492.0K | $506.0K | $521.0K |
| Other Current Liab | $0 | $0 | $346.0K |
| Long-Term Liabilities | $1.3M | $888.0K | $421.0K |
| LT Operating Leases | $1.3M | $888.0K | $421.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $5.0M | $2.7M | $4.2M |
| Shareholders' Equity | $15.3M | $3.6M | $10.5M |
| Retained Earnings | $-325.0M | $-339.7M | $-342.2M |
| AOCI | $2.0K | $0 | — |
| Total L&E | $20.3M | $6.3M | $14.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-17.3M | $-14.7M | $-2.5M |
| Non-Cash Adjustments | $2.7M | $2.1M | $-9.0M |
| Working Capital Changes | $2.2M | $-2.0M | $2.0M |
| Cash from Operations | $-12.4M | $-14.7M | $-9.5M |
| Capital Expenditures | $396.0K | $42.0K | $13.0K |
| Cash from Investing | $-966.0K | $816.0K | $9.0M |
| Cash from Financing | $0 | $1.4M | $8.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-13.4M | $-12.4M | $8.4M |
| Beginning Cash | $28.8M | $15.4M | $3.0M |
| Ending Cash | $15.4M | $3.0M | $11.5M |
Frequently Asked Questions
How does VivoSim Labs, INC. make money?
The company's revenue primarily stems from research and development activities, with minimal commercial sales recorded in recent years. Operations are driven by internal R&D spend on oncology assets rather than diversified product lines or licensing agreements at this stage.
What are the main risks for VIVS?
High risk of clinical trial failure leading to total loss of invested R&D capital. Severe cash burn with negative operating cash flow requiring continuous equity financing or asset monetization. Prolonged development timelines and regulatory uncertainty in the oncology space. Dependence on successful partnerships or future commercial milestones to sustain liquidity.
What is VIVS's competitive advantage?
Access to proprietary molecular targets and innovative drug delivery mechanisms that could differentiate their pipeline. A lean operational structure allowing for strategic flexibility despite current losses. Potential for significant value creation upon successful clinical trial readouts and regulatory approvals.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.